Company Filing History:
Years Active: 2025
Title: Alan Shuldiner: Innovator in Gene Therapy
Introduction: Alan Shuldiner is a prominent inventor based in Baltimore, MD, recognized for his significant contribution to the field of gene therapy through his patent related to ribonucleic acid (RNA) compositions. With a focus on innovative solutions for health conditions linked to gene expression, Shuldiner's work embodies the spirit of scientific advancement.
Latest Patents: Alan Shuldiner holds a patent for "17ß-hydroxysteroid dehydrogenase type 13 (HSD17B13) iRNA compositions and methods of use thereof." This invention pertains to double-stranded RNA compositions targeting the HSD17B13 gene. The patent details methods for inhibiting the expression of HSD17B13 and outlines therapeutic approaches for treating subjects suffering from HSD17B13-associated diseases or conditions through these RNA compositions.
Career Highlights: Currently, Alan Shuldiner works with Regeneron Pharmaceuticals, Inc., a company renowned for its innovative biomedical research and development. His role involves leveraging his expertise in molecular biology and gene therapy to contribute to groundbreaking advancements in medicine. The patent he secured showcases his commitment to addressing serious health issues through scientific exploration.
Collaborations: Throughout his career, Alan has collaborated with notable colleagues, including Gregory Hinkle and Frederic Tremblay. These collaborations have likely fostered a dynamic environment for innovation, combining their expertise to further enhance the impact of their research efforts.
Conclusion: Alan Shuldiner's contributions to the field of gene therapy, particularly through his patent involving HSD17B13, highlight the vital role of innovators in advancing medical science. His work at Regeneron Pharmaceuticals, Inc., along with collaborative efforts with esteemed coworkers, underscores the importance of teamwork in driving forward the boundaries of innovation in healthcare.